Skip to Content

Join the 'Defitelio' group to help and get support from people like you.

Defitelio News

FDA Approves Defitelio (defibrotide sodium) for Hepatic Veno-Occlusive Disease Following Hematopoietic Stem-Cell Transplantation

Posted 31 Mar 2016 by

March 30, 2016 – The U.S. Food and Drug Administration today approved Defitelio (defibrotide sodium) to treat adults and children who develop hepatic veno-occlusive disease (VOD) with additional kidney or lung abnormalities after they receive a stem cell transplant from blood or bone marrow called hematopoietic stem cell transplantation (HSCT). This is the first FDA-approved therapy for ...

Ask a Question

Further Information

Related Condition Support Groups

Hepatic veno-occlusive disease

Defitelio Patient Information at